Dec 26, 2025 • Sahm
BULLISH
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
An investment of $100 in Viking Therapeutics (NASDAQ: VKTX) five years ago would be worth $634.13 today, reflecting an average annual return of 46.0%. The company has outperformed the market by 32.8% on an annualized basis over this period, highlighting the significant impact of compounded returns.
Dec 25, 2025 • Yahoo! Finance Canada
BULLISH
Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program
Viking Therapeutics (VKTX) saw an 8.9% increase in its stock after competitor Eli Lilly's successful Phase 3 oral obesity study provided external validation for Viking's own oral obesity drug program. Analyst Joseph Pantginis of H.C. Wainwright reaffirmed a positive stance on Viking, highlighting the potential of its lead candidate VK2735 in the growing obesity treatment market. Despite this positive development, the company, which currently has no revenue and ongoing losses, still relies heavily on the outcomes of its own VK2735 trials and future funding decisions.
Dec 25, 2025 • Simply Wall Street
SOMEWHAT-BULLISH
Viking Therapeutics (VKTX): Revisiting Valuation After a Renewed Share Price Rally
Viking Therapeutics (VKTX) has seen a significant share price rally, prompting a re-evaluation of its valuation. Despite being down year-to-date, a recent 49% increase over 90 days suggests renewed investor interest in its pipeline, particularly considering its price-to-book ratio relative to peers and the broader biotech sector. The article explores whether Viking Therapeutics is an undervalued growth story or if its future success is already priced in, highlighting key risks and upside potential.
Dec 25, 2025 • Yahoo Finance
SOMEWHAT-BULLISH
Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program
Viking Therapeutics (VKTX) surged 8.9% after rival Eli Lilly's successful Phase 3 oral obesity study provided external validation for Viking's own oral obesity drug candidate, VK2735. This bolsters investor confidence in Viking's potential role in the obesity treatment market, though the company, currently unprofitable, still critically depends on its own trial outcomes and future financing.
Dec 24, 2025 • www.sharewise.com
SOMEWHAT-BEARISH
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) saw a 2.85% increase in its stock price, outperforming the S&P 500, Dow, and Nasdaq in the latest trading session. While VKTX has appreciated over the past month, it lagged the S&P 500 but still beat its sector. The company is anticipated to report a significant drop in EPS for the upcoming earnings report, with analysts closely monitoring estimate revisions for insights into its future stock performance.
Dec 23, 2025 • Simply Wall Street
SOMEWHAT-BULLISH
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Fresh Validation Of Oral Obesity Drugs
Analysts have reiterated positive views on Viking Therapeutics (VKTX) after competitor Eli Lilly reported supportive Phase 3 results for an oral obesity therapy, reinforcing confidence in Viking's lead candidate VK2735 and its metabolic pipeline. This external validation, combined with bullish analyst coverage, positions Viking as a potential key player in the obesity and NASH markets, despite its current lack of approved products and rising losses. The company's investment narrative now hinges on converting strong mid-stage data into successful late-stage trials and commercial products, with key milestones remaining VK2735 and VK2809 readouts.